Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes (REACS)
This study has been completed.
Information provided by (Responsible Party):
Nadine Ajzenberg, Institut National de la Santé Et de la Recherche Médicale, France
First received: March 2, 2006
Last updated: December 27, 2011
Last verified: December 2011
The purpose of this study is to determine whether shear-induced platelet aggregation is able to discriminate first acute coronary syndrome (ACS) from recurrent ACS
||Observational Model: Case Control
Time Perspective: Prospective
||Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes
Biospecimen Retention: Samples Without DNA
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2009 (Final data collection date for primary outcome measure)
Predictive factors of recurrence of ACS are not well determined. Platelet aggregation and leucocyte activation seem to be involved in the pathogenesis. The aim of our study is to compare SIPA, platelet activation and platelet-leucocytes aggregates on the onset of the ACS and 3 months later in 2 groups of patients scheduled for a first episode of ACS or recurrent ACS .
|Ages Eligible for Study:
||18 Years to 85 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
patients admitted in the intensive care unit with acute coronary syndrome
over 18 years old. informed consent signed. acute coronary syndrome not associated with co-morbidity as bleeding diathesis or myocardial infarction during the procedure.
clinical symptoms in agreement with myocardial infarction during the preceding 24 hours.
CK OR troponin elevation and one or more of the following criteria: ECG modifications transient ST elevation>1 mm. new inversion of ST <1 mm on 2 contiguous derivations.
Acute coronary syndrome with persistent ST elevation. Angioplasty in emergency before blood sampling. Inflammatory disease or cancer. Coagulation abnormalities. Antiphospholipid syndrome. Treatment by vitamin K antagonist. Severe disease with life expectancy lower than 2 years. One-year follow up impossible.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00299143
|Paris, France, 75018 |
Institut National de la Santé Et de la Recherche Médicale, France
||Philippe G Steg, Professor
||Nadine Ajzenberg, Dr
No publications provided
||Nadine Ajzenberg, professor, Institut National de la Santé Et de la Recherche Médicale, France
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 2, 2006
||December 27, 2011
||France: National Consultative Ethics Committee for Health and Life Sciences
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
acute coronary syndrome
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 19, 2014
Acute Coronary Syndrome
Signs and Symptoms